keyword
MENU ▼
Read by QxMD icon Read
search

urothelium cancer

keyword
https://www.readbyqxmd.com/read/29143738/bladder-cancer-associated-mutations-in-rxra-activate-peroxisome-proliferator-activated-receptors-to-drive-urothelial-proliferation
#1
Angela M Halstead, Chiraag D Kapadia, Jennifer Bolzenius, Clarence E Chu, Andrew Schriefer, Lukas D Wartman, Gregory R Bowman, Vivek K Arora
RXRA regulates transcription as part of a heterodimer with 14 other nuclear receptors, including the peroxisome proliferator-activated receptors (PPARs). Analysis from the TCGA raised the possibility that hyperactive PPAR signaling, either due to PPAR gamma gene amplification or RXRA hot-spot mutation (S427F/Y) drives 20-25% of human bladder cancers. Here we characterize mutant RXRA, demonstrating it induces enhancer/promoter activity in the context of RXRA/PPAR heterodimers in human bladder cancer cells. Structure-function studies indicate that the RXRA substitution allosterically regulates the PPAR AF2 domain via an aromatic interaction with the terminal tyrosine found in PPARs...
November 16, 2017: ELife
https://www.readbyqxmd.com/read/29077785/impact-of-contemporary-patterns-of-chemotherapy-utilization-on-survival-in-patients-with-advanced-cancer-of-the-urinary-tract-a-retrospective-international-study-of-invasive-advanced-cancer-of-the-urothelium-risc
#2
A Bamias, K Tzannis, L C Harshman, S J Crabb, Y-N Wong, S Kumar Pal, U De Giorgi, S Ladoire, N Agarwal, E Y Yu, G Niegisch, A Necchi, C N Sternberg, S Srinivas, A Alva, U Vaishampayan, L Cerbone, M Liontos, J Rosenberg, T Powles, J Belmunt, M D Galsky
BackgroundCisplatin-based combination chemotherapy is the standard treatment for advanced urinary tract cancer (aUTC) but 50% of patients are ineligible for cisplatin according to recently published criteria. We used a multinational database to study patterns of chemotherapy utilization in patients with aUTC and determine their impact on survival.Patients and MethodsThis was a retrospective study of patients with: UTC (bladder, renal pelvis, ureter or urethra); advanced disease (stages T4b and/or N+ and/or M+); urothelial, squamous or adenocarcinoma histology...
October 25, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29066888/drug-delivery-system-based-on-dendritic-nanoparticles-for-enhancement-of-intravesical-instillation
#3
Xuefeng Qiu, Kai Cao, Tingsheng Lin, Wei Chen, Ahu Yuan, Jinhui Wu, Yiqiao Hu, Hongqian Guo
Intravesical instillation of antitumor agents following transurethral resection of bladder tumors is the standard strategy for the treatment of superficial bladder cancers. However, the efficacy of current intravesical instillation is limited partly due to the poor permeability of the urothelium. We therefore aimed to develop a high-penetrating, target-releasing drug delivery system to improve the efficacy of intravesical instillation. PAMAM, a dendrimer, were conjugated with polyethylene glycol (PEG) to form PEG-PAMAM complex as a nanocarrier...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29066225/urinary-tissue-engineering-challenges-and-opportunities
#4
REVIEW
Anirudha Singh, Trinity J Bivalacqua, Nikolai Sopko
INTRODUCTION: In this review, we discuss major advancements and common challenges in constructing and regenerating a neo-urinary conduit (NUC). First, we focus on the need for regenerating the urothelium, the hallmark the urine barrier, unique to urinary tissues. Second, we focus on clinically feasible scaffolds based on decellularized matrices and molded collagen that are currently of great research interest. AIM: To discuss the major advancements in constructing a tissue-engineered NUC (TE-NUC) and the challenges involved in their successful clinical translation...
October 21, 2017: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/29016672/the-interaction-of-arsenic-and-n-butyl-n-4-hydroxybutyl-nitrosamine-on-urothelial-carcinogenesis-in-mice
#5
Yuan-Chang Dai, Shou-Chieh Wang, Mohammad Mezbahul Haque, Wei-Han Lin, Lei-Chen Lin, Ching-Hsein Chen, Yi-Wen Liu
The bladder is an important organ for the storage of excreted water and metabolites. If metabolites with carcinogenic characteristics are present in urine, the urothelial lining of the bladder could be damaged and genetically altered. In this study, we analyzed the interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) on mouse bladder carcinogenesis. Our previous study found that arsenic affects BBN-altered urothelial enzymatic activity, protein expression, DNA oxidation and global DNA CpG methylation levels...
2017: PloS One
https://www.readbyqxmd.com/read/28959653/p-benzoquinone-initiates-non-invasive-urothelial-cancer-through-aberrant-tyrosine-phosphorylation-of-egfr-map-kinase-activation-and-cell-cycle-deregulation-prevention-by-vitamin-c
#6
Shinjini Ganguly, Ayan Chandra, Dhruba J Chattopadhyay, Indu B Chatterjee
According to WHO classification system, non-invasive urothelial carcinoma represents urothelial carcinoma in situ (CIS) and dysplasia. Dysplastic urothelium often progresses to CIS that further advances to urothelial carcinoma (UC). The strongest risk factor for UC is cigarette smoking. However, the pathogenesis of cigarette smoke (CS)-induced UC is poorly understood. Earlier we had shown that p-benzoquinone (p-BQ), a major toxic quinone derived from p-benzosemiquinone of CS in vivo, is a causative factor for various CS-induced diseases...
2017: Toxicology Reports
https://www.readbyqxmd.com/read/28938585/the-trophoblast-cell-surface-antigen-2-and-mir-125b-axis-in-urothelial-bladder-cancer
#7
Chiara Avellini, Caterina Licini, Raffaella Lazzarini, Rosaria Gesuita, Emanuela Guerra, Giovanni Tossetta, Clara Castellucci, Stefano Raffaele Giannubilo, Antonio Procopio, Saverio Alberti, Roberta Mazzucchelli, Fabiola Olivieri, Daniela Marzioni
Human trophoblast cell surface antigen 2 (Trop-2) is a 40-kDa transmembrane glycoprotein that was first identified as a marker of human trophoblast cells. Trop-2 acts on cell proliferation, adhesion, and migration by activating a number of intracellular signalling pathways. Elevated Trop-2 expression has been demonstrated in several types of cancer and correlated with aggressiveness and poor prognosis. Since no data are available on Trop-2 in bladder cancer (BC), the purpose of the study was to determine its levels in tissue specimens from normal individuals and patients with BC at different stages...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28916750/comprehensive-multiregional-analysis-of-molecular-heterogeneity-in-bladder-cancer
#8
Mathilde Borg Houlberg Thomsen, Iver Nordentoft, Philippe Lamy, Søren Vang, Line Reinert, Christophe Kamungu Mapendano, Søren Høyer, Torben F Ørntoft, Jørgen Bjerggaard Jensen, Lars Dyrskjøt
Genetic alterations identified in adjacent normal appearing tissue in bladder cancer patients are indicative of a field disease. Here we assessed normal urothelium transformation and intra-tumour heterogeneity (ITH) in four patients with bladder cancer. Exome sequencing identified private acquired mutations in a lymph node metastasis and local recurrences. Deep re-sequencing revealed presence of at least three and four subclones in two patients with multifocal disease, while no demarcation of subclones was identified in the two patients with unifocal disease...
September 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28888113/tissue-engineered-human-3d-model-of-bladder-cancer-for-invasion-study-and-drug-discovery
#9
Cassandra Ringuette Goulet, Geneviève Bernard, Stéphane Chabaud, Amélie Couture, Alexandre Langlois, Bertrand Neveu, Frédéric Pouliot, Stéphane Bolduc
The tumour microenvironment is critical to both the initiation and maintenance of tumorigenesis. Reconstitution of the microenvironment is a major challenge for in vitro cancer models. Indeed, conventional 2D culture systems cannot replicate the complexity, diversity and dynamic nature of the tumour microenvironment. In this study, we have developed a 3D endotheliazed vesical equivalent by using tissue engineering from primary human cells in which non-invasive or invasive bladder cancer (BCa) cell lines, cultured as compact spheroids, were incorporated...
August 29, 2017: Biomaterials
https://www.readbyqxmd.com/read/28882129/igf1r-activation-and-the-in-vitro-antiproliferative-efficacy-of-igf1r-inhibitor-are-inversely-correlated-with-igfbp5-expression-in-bladder-cancer
#10
Yann Neuzillet, Elodie Chapeaublanc, Clémentine Krucker, Leanne De Koning, Thierry Lebret, François Radvanyi, Isabelle Bernard-Pierrot
BACKGROUND: The insulin growth factor (IGF) pathway has been proposed as a potential therapeutic target in bladder cancer. We characterized the expression of components of the IGF pathway - insulin growth factor receptors (INSR, IGF1R, IGF2R), ligands (INS, IGF1, IGF2), and binding proteins (IGFBP1-7, IGF2BP1-3) - in bladder cancer and its correlation with IGF1R activation, and the anti-proliferative efficacy of an IGF1R kinase inhibitor in this setting. METHODS: We analyzed transcriptomic data from two independent bladder cancer datasets, corresponding to 200 tumoral and five normal urothelium samples...
September 7, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28871659/overexpression-of-her-2-via-immunohistochemistry-in-canine-urinary-bladder-transitional-cell-carcinoma-a-marker-of-malignancy-and-possible-therapeutic-target
#11
F Millanta, J Impellizeri, L McSherry, G Rocchigiani, L Aurisicchio, G Lubas
Transitional cell carcinoma (TCC) is the most commonly diagnosed neoplasm in the urinary bladder. Distant metastases to the regional lymph nodes, lungs, abdominal organs or bones are noted in up to 50% of dogs at time of death. Surgical excision is often not practical as TCC typically involve the trigone of the bladder and/or occurs multifocally throughout the bladder with field cancerization. Therapeutic approaches are very challenging and the requirement to evaluate alternative therapeutic protocols that may prolong survival times in dogs bearing these tumours is compelling...
September 4, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28843746/cytological-and-histological-changes-in-the-urothelium-produced-by-electromotive-drug-administration-emda-and-by-the-combination-of-intravescical-hyperthermia-and-chemotherapy-thermochemotherapy
#12
Francesco Pierconti, Patrizia Straccia, Sacco Emilio, Pier Francesco Bassi, Ivana De Pascalis, Rita C Marques, Metka Volavsek, Luigi M Larocca, Antonio Lopez-Beltran
The treatment of non muscle-invasive bladder cancer (NMIBC) encompasses a range of different procedures. Electromotive drug administration (EMDA) and chemo-hyperthermia (C-HT; Synergo) represent a minimally-invasive methods of intravesical instillation of therapeutic agents as mitomycin C (MMC). We selected patients with high grade NMIBC, BCG non responder, treated with EMDA/MMC and C-HT/MMC and we also examined the morphological changes in urine cytology samples. During the period from 2012 to 2014, 110 patients with high grade NMIBC, BCG refractory were selected...
August 1, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28831205/phosphorylated-mtor-expression-profiles-in-human-normal-and-carcinoma-tissues
#13
Hojung Lee
Mammalian target of rapamycin (mTOR) is a key controller of cell growth and proliferation in normal tissues and solid tumors. In the present study, an immunohistochemical analysis of the expression pattern of phosphorylated mTOR (p-mTOR) was performed in human normal fetal and adult tissues and various carcinoma tissues. p-mTOR expression showed tissue and cell type specificity in normal and cancer tissues. In normal fetal and adult tissues, p-mTOR staining was observed in the intestinal crypt, intrahepatic bile ductule, pancreatic duct, distal nephron of the kidney, umbrella cell of urothelium, mesothelial cell, and choroid plexus...
2017: Disease Markers
https://www.readbyqxmd.com/read/28818454/the-anti-tumor-effect-of-intravesical-administration-of-normal-urothelial-cells-on-bladder-cancer
#14
Chi-Ping Huang, Chi-Cheng Chen, Chih-Rong Shyr
BACKGROUND AIMS: Urothelial bladder cancer (UBC) is the second most common cancer of the genitourinary tract and for advanced forms of the disease it has a high mortality rate. There are no approved new molecularly targeted agents or chemotherapeutics for advanced UBC beyond cisplatin-based chemotherapy except the recently approved anti-programmed death ligand 1 (anti-PD-1/PD-L1) antibody. With complex genetic and epigenetic alterations in tumors, despite several druggable targets identified, to cure UBC is still a challenging unmet medical need...
August 14, 2017: Cytotherapy
https://www.readbyqxmd.com/read/28816296/-complete-androgen-insensitivity-syndrome-associated-with-vesical-fistula-a-case-report-and-literature-review
#15
K H Hua, L Yang, X W Zhang, W J Bai, Q Li, T Xu
Androgen insensitivity syndrome (AIS) is a very uncommon genetic disorder that results from the resistance of androgen receptor (AR) to androgen, which influences the formation of the male genitalia and in turn presents with female phenotype. Surgical resection of undesceaded testicle and different kinds of genitoplasty are crucial methods to correct the deformity of reproductive system, as well as hormone replacement therapy, which is an essential therapy for postoperational rehabilitation in AIS patients...
August 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/28766915/metabolomics-analysis-reveals-distinct-profiles-of-nonmuscle-invasive-and-muscle-invasive-bladder-cancer
#16
Divya Sahu, Yair Lotan, Bryan Wittmann, Bruce Neri, Donna E Hansel
Urothelial carcinoma is the most common form of bladder cancer, but pathway changes that occur with stage-wise progression have not been well defined. We used a metabolomics approach to identify potential metabolic pathways uniquely altered in normal urothelium, nonmuscle-invasive bladder cancer (NMIBC), and muscle-invasive bladder cancer (MIBC). We performed global metabolomic profiling using GC-mass spectrometry (MS) and LC-MS platforms to identify metabolite signatures between normal urothelium and high-grade urothelial carcinoma of different stages...
September 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28753897/lack-of-effectiveness-of-postchemotherapy-lymphadenectomy-in-bladder-cancer-patients-with-clinical-evidence-of-metastatic-pelvic-or-retroperitoneal-lymph-nodes-only-a-propensity-score-based-analysis
#17
Andrea Necchi, Luigi Mariani, Salvatore Lo Vullo, Evan Y Yu, Michael E Woods, Yu-Ning Wong, Lauren C Harshman, Ajjaj Alva, Cora N Sternberg, Aristotelis Bamias, Petros Grivas, Vadim S Koshkin, Florian Roghmann, Jakub Dobruch, Bernie J Eigl, Lucia Nappi, Matthew I Milowsky, Guenter Niegisch, Sumanta K Pal, Ugo De Giorgi, Federica Recine, Ulka Vaishampayan, Dominik D Berthold, Daniel W Bowles, Jack Baniel, Christine Theodore, Sylvain Ladoire, Sandy Srinivas, Neeraj Agarwal, Simon Crabb, Srikala Sridhar, Ali-Reza Golshayan, Carsten Ohlmann, Evanguelos Xylinas, Thomas Powles, Johnathan E Rosenberg, Joaquim Bellmunt, Bas van Rhijn, Matthew D Galsky, Kees Hendricksen
BACKGROUND: Limited data is available on the role, and extent of, postchemotherapy lymphadenectomy (PC-LND) in patients with clinical evidence of pelvic (cN1-3) or retroperitoneal (RP) lymph node spread from urothelial bladder carcinoma. OBJECTIVE: To compare the outcomes of operated versus nonoperated patients after first-line chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: Data from 34 centers was collected, totaling 522 patients, treated between January 2000 and June 2015...
June 3, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753879/robot-assisted-versus-open-radical-cystectomy-in-patients-receiving-perioperative-chemotherapy-for-muscle-invasive-bladder-cancer-the-oncologist-s-perspective-from-a-multicentre-study
#18
Andrea Necchi, Gregory R Pond, Marc C Smaldone, Sumanta K Pal, Kevin Chan, Yu-Ning Wong, Rosalia Viterbo, Guru Sonpavde, Lauren C Harshman, Simon Crabb, Ajjai Alva, Simon Chowdhury, Ugo De Giorgi, Sandy Srinivas, Neeraj Agarwal, Aristotelis Bamias, Jack Baniel, Ali-Reza Golshayan, Sylvain Ladoire, Cora N Sternberg, Linda Cerbone, Evan Y Yu, Joaquim Bellmunt, Ulka Vaishampayan, Gunter Niegisch, Syed Hussain, Daniel W Bowles, Rafael Morales-Barrera, Matthew I Milowsky, Christine Theodore, Dominik R Berthold, Srikala S Sridhar, Thomas Powles, Jonathan E Rosenberg, Matthew D Galsky
BACKGROUND: Little is known about the outcomes of robot-assisted radical cystectomy (RARC) compared to open radical cystectomy (ORC) combined with perioperative chemotherapy for muscle-invasive urothelial bladder cancer (UBC). OBJECTIVE: To evaluate surgical and oncological outcomes for RARC and ORC in multimodal treatment. DESIGN, SETTING, AND PARTICIPANTS: Data from 28 centres were collected for cystectomies performed between January 2000 and July 2013...
March 31, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28751166/clinical-and-demographic-characteristics-among-patients-with-urothelial-carcinomas-of-the-upper-urinary-tract-and-bladder-in-taiwan
#19
Cheng-Huang Shen, Hung-Yi Chiou, Min-Che Tung, Chia-Chang Wu, Wei-Tang Kao, Yuan-Hung Wang, Guang-Dar Juang
BACKGROUND: Urothelial carcinoma (UC) is derived from the urothelium of the urinary tract, and includes cancers of the bladder, renal pelvis and ureter. The aim of this study was to investigate the clinical and demographic features among patients with bladder cancer and urothelial carcinoma of the upper urinary tract (UTUC) in Taiwan. METHODS: The present study recruited a total of 736 histopathologically confirmed UC cases, which consisted of 470 bladder cancer and 266 UTUC between September 1998 and December 2009...
July 24, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/28749907/immunotherapy-in-urothelial-cancer-part-1-t-cell-checkpoint-inhibition-in-advanced-or-metastatic-disease
#20
Steven S Yu, Tanya B Dorff, Leslie K Ballas, Sarmad Sadeghi, Eila C Skinner, David I Quinn
Cancer of the urothelium is the sixth most common cancer in the United States and is seen predominantly in men. Most cases of this disease present as non-muscle-invasive bladder cancer (NMIBC), with cancer recurrence or progression to muscle-invasive cancer in more than 50% of patients after initial therapy. NMIBC is an immune-responsive disease, as indicated by the use of intravesical bacillus Calmette-Guérin as treatment for more than 3 decades. More recently, immunotherapy has seen much progress in a variety of cancers, including advanced and metastatic bladder cancer, in which historical 5-year survival rates are approximately 15%...
June 2017: Clinical Advances in Hematology & Oncology: H&O
keyword
keyword
53999
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"